The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma

References

• 1. Terzolo M, Daffara F, Ardito A et al. Management of adrenal cancer: a 2013 update. J. Endocrinol. Invest. 37(3), 207–217 (2014).
  Medline CASGoogle Scholar
• 2. Grisanti S, Cosentini D, Laganà M et al. Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures. Curr. Opin. Endocr. Metab. Res. 8, 80–87 (2019).
  Google Scholar
• 3. Bonneville R, Krook MA, Kautto EA et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis. Oncol. 1, PO.17.00073 (2017).
  Google Scholar
• 4. Le DT, Durham JN, Smith KN et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409–413 (2017).
  Medline CASGoogle Scholar
• 5. Chang LS, Barroso-Sousa R, Tolaney SM et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40(1), 17–65 (2019).
  MedlineGoogle Scholar
• 6. Tierney JF, Vogle A, Poirier J et al. Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: an exploratory study. Surgery 165(1), 196–201 (2019).
  MedlineGoogle Scholar
• 7. Brabo EP, Moraes AB, Neto LV. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. J. Endocrinol. Invest. 43(11), 1531–1542 (2020).
  Medline CASGoogle Scholar
• 8. Le Tourneau C, Hoimes C, Zarwan C et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial. J. Immunother. Cancer. 6(1), 111 (2018).
  MedlineGoogle Scholar
• 9. Habra MA, Stephen B, Campbell M et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J. Immunother. Cancer. 7(1), 253 (2019).
  MedlineGoogle Scholar
• 10. Raj N, Zheng Y, Kelly V et al. PD-1 blockade in advanced adrenocortical carcinoma. J. Clin. Oncol. 38(1), 71–80 (2020).
  Medline CASGoogle Scholar
• 11. Carneiro B, Konda B, Costa RB et al. Nivolumab in metastatic adrenocortical carcinoma: results of a Phase 2 trial. J. Clin. Endocrinol. Metab. 104(12), 6193–6200 (2019).
  MedlineGoogle Scholar
• 12. Fojo AT. Immunotherapy for adrenocortical cancer. Semin. Oncol. 46(1), 1–2 (2019).
  MedlineGoogle Scholar
• 13. Henning JEK, Deutschbein T, Altieri B et al. Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J. Clin. Endocrinol. Metab. 102(11), 4323–4332 (2017).
  MedlineGoogle Scholar
• 14. Cosentini D, Badalamenti G, Grisanti S et al. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur. J. Endocrinol. 181(6), 681–689 (2019).
  Medline CASGoogle Scholar
• 15. Ambrosini R, Balli MC, Laganà M et al. Adrenocortical carcinoma and CT assessment of therapy response: the value of combining multiple criteria. Cancers 12(6), 1395 (2020).
  CASGoogle Scholar
• 16. Cosentini D, Grisanti S, Dalla Volta A et al. Immunotherapy failure in adrenocortical cancer: where next? Endocr. Connect. 7(12), E5–E8 (2018).
  Medline CASGoogle Scholar
• 17. Fiorentini C, Grisanti S, Cosentini D et al. Molecular drivers of potential immunotherapy failure in adrenocortical carcinoma. J. Oncol. 2019, 6072863 (2019).
  MedlineGoogle Scholar
• 18. Zheng S, Cherniack AD, Dewal N et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29(5), 723–736 (2016).
  Medline CASGoogle Scholar
• 19. Landwehr LS, Altieri B, Schreiner J et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J. Immunother. Cancer. 8(1), e000469 (2020).
  MedlineGoogle Scholar
• 20. Wang S, He Z, Wang X et al. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. eLife. 8, e49020 (2019).
  Medline CASGoogle Scholar